MMWR Morb Mortal Wkly Rep. 2022 Jun 3;71(22):734-742. doi: 10.15585/mmwr.mm7122e1.
Certain laboratorians and health care personnel can be exposed to orthopoxviruses through occupational activities. Because orthopoxvirus infections resulting from occupational exposures can be serious, the Advisory Committee on Immunization Practices (ACIP) has continued to recommend preexposure vaccination for these persons since 1980 (1), when smallpox was eradicated (2). In 2015, ACIP made recommendations for the use of ACAM2000, the only orthopoxvirus vaccine available in the United States at that time (3). During 2020-2021, ACIP considered evidence for use of JYNNEOS, a replication-deficient Vaccinia virus vaccine, as an alternative to ACAM2000. In November 2021, ACIP unanimously voted in favor of JYNNEOS as an alternative to ACAM2000 for primary vaccination and booster doses. With these recommendations for use of JYNNEOS, two vaccines (ACAM2000 and JYNNEOS) are now available and recommended for preexposure prophylaxis against orthopoxvirus infection among persons at risk for such exposures.
某些实验室人员和医护人员可能会因职业活动而接触正痘病毒。由于职业暴露导致的正痘病毒感染可能很严重,因此自 1980 年(1)天花被根除以来(2),免疫实践咨询委员会(ACIP)一直建议这些人进行暴露前疫苗接种。2015 年,ACIP 就 ACAM2000 的使用提出了建议,这是当时美国唯一可用的正痘病毒疫苗(3)。在 2020-2021 年期间,ACIP 考虑了使用 JYNNEOS(一种复制缺陷的牛痘病毒疫苗)作为 ACAM2000 的替代方案的证据。2021 年 11 月,ACIP 一致投票赞成 JYNNEOS 作为 ACAM2000 的替代方案,用于初级疫苗接种和加强剂量。随着对 JYNNEOS 使用的这些建议,现在有两种疫苗(ACAM2000 和 JYNNEOS)可用于预防正痘病毒感染,并建议接触风险人群进行暴露前预防。